Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

Launched by CASE COMPREHENSIVE CANCER CENTER · Oct 10, 2023

Keywords

ClinConnect Summary

The TRANSCAPE trial is a study looking at a new treatment option for patients with a specific type of cancer called pseudomyxoma peritonei (PMP), which affects the abdominal area and is not treatable with standard methods. The goal is to see if intestinal or multivisceral transplantation (a complex surgery where multiple organs are transplanted) can effectively help patients whose cancer cannot be surgically removed. This study will involve patients aged 18 to 75 who have been diagnosed with PMP, including those with low or high-grade cancer, and who have no other treatment options available.

Participants in the trial will undergo the transplantation procedure and will be monitored for one year to evaluate how well the treatment works and if it is safe. It’s important to know that the trial is not yet recruiting participants, and individuals must meet specific criteria to join, including having extensive PMP without significant metastasis to other organs. If accepted, participants will need to sign a consent form and will be closely followed by the medical team throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects must have histologically confirmed pseudomyxoma peritonei (PMP)
• • Both low-grade mucinous carcinoma peritonei (LMCP) or high-grade mucinous carcinoma (HMCP), with or without signet ring cells as well as primary or recurrent disease, will be eligible.
• • PMP disease does not have any extra-abdominal metastases, with the exception of pulmonary involvement (nodal, parenchymal, and pleural).
• • PMP disease is extensive and not amenable to operative management, with or without liver, pancreas, stomach, or abdominal wall involvement.
• • Definition of Non-Resectable Disease-
• * Non-resectable PMP disease will be defined as the presence of at least one of the following conditions:
• • 1) Extensive small bowel serosa involvement, where it is not possible to preserve at least 1.5-2 m of small bowel
• • 2) Extensive infiltration of the pancreatic surface
• • 3) Mesenteric involvement causing retraction
• • 4) Need for complete gastric resection
• • 5) Urete1ic obstruction
• • 6) Liver disease with no chance to achieve R0 resection with liver remnant volume \> 30%
• • 7) Recurrent disease not amenable to further resection
• • Subjects do not have any other available curative treatment options.
• • Subjects can have previous abdominal operations, including CRS+HIPEC.
• • Age ≥ 18 and ≤ 75.
• • Pediatric participants were excluded as PMP is a disease that affects adults. Participants \> 75 years of age are excluded as they are beyond the commonly accepted transplantability criteria.
• • Performance status ECOG ≤ 1.
• • Subjects must have the ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Subjects with peritoneal carcinomatous originating from an etiology other than PMP.
• • Subjects receiving any other investigational agents.
• • Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would either put participation at risk because of participation in the study, may influence the result of the study, or limit compliance with study requirements.
• • Pregnant women are excluded from this study because an intestinal transplant is a procedure that is not compatible with a viable pregnancy.
• • Subjects who are HIV-positive may be included in the study. HIV testing is required for the study as adequate HIV treatment is required prior to intestinal transplant due to the increased risk of infection following transplantation and treatment with immunosuppressive agents.